Daily Endocrinology Research Analysis
Across endocrinology and metabolism, three studies stand out: an umbrella review of RCT meta-analyses maps the broad cardio-renal-metabolic benefits and adverse effects of GLP-1 receptor agonists; a genetic study links type 2 diabetes’ hyperinsulinemia pathway to vascular dementia risk; and a mechanistic paper uncovers a PKM2–histone lactylation–3D genome program driving PCOS-like phenotypes and reversibility in vivo.
Summary
Across endocrinology and metabolism, three studies stand out: an umbrella review of RCT meta-analyses maps the broad cardio-renal-metabolic benefits and adverse effects of GLP-1 receptor agonists; a genetic study links type 2 diabetes’ hyperinsulinemia pathway to vascular dementia risk; and a mechanistic paper uncovers a PKM2–histone lactylation–3D genome program driving PCOS-like phenotypes and reversibility in vivo.
Research Themes
- GLP-1 receptor agonists: comprehensive benefits and risks across systems
- Metabolic-brain genetics: hyperinsulinemia pathway and vascular dementia
- Epigenetic chromatin remodeling in PCOS pathophysiology
Selected Articles
1. Efficacy and safety of glucagon-like peptide 1 receptor agonists across all health outcomes in type 2 diabetes: An umbrella review and evidence map of randomised controlled trials.
Across 17 umbrella meta-analyses synthesizing 432 RCTs and 65 outcomes, GLP-1RAs reduced heart failure (eOR 0.71), peripheral artery disease (0.75), kidney composite outcomes (0.76), nephropathy (0.74), and albuminuria (0.73), and improved weight (0.46) and HbA1c (0.83). Gastrointestinal adverse events were increased (e.g., nausea eOR 9.62), while no meaningful cancer signal emerged. Some drugs showed outcome-specific strengths (liraglutide for MACE, albiglutide for MI, dulaglutide for stroke).
Impact: This work provides the most comprehensive, methodologically appraised synthesis of GLP-1RA benefits and risks across systems, informing evidence-based selection and counseling.
Clinical Implications: Supports prioritizing GLP-1RAs for T2D patients with cardiorenal risk, while counseling on common GI adverse events and tailoring drug choice to outcome priorities.
Key Findings
- Reduced heart failure risk (eOR 0.71, 95% CI 0.64–0.79) and peripheral artery disease (0.75, 0.67–0.84).
- Renal benefits: lower kidney composite outcomes (eOR 0.76), nephropathy (0.74), and albuminuria (0.73).
- Metabolic improvements: greater weight loss (eOR 0.46) and HbA1c reduction (0.83).
- Increased gastrointestinal adverse events: nausea (eOR 9.62), dyspepsia (4.85), constipation (3.39).
- Drug-specific signals: liraglutide, albiglutide, and dulaglutide showed differential protection for MACE, MI, and stroke.
Methodological Strengths
- Umbrella review of 17 meta-analyses covering 432 RCTs with AMSTAR 2 appraisal and GRADE certainty.
- Pre-registered protocol (PROSPERO) and harmonized effect size conversion to equivalent odds ratios.
Limitations
- Certainty for several outcomes was low to very low; heterogeneity across trials and populations persists.
- Reliance on study-level meta-analyses without individual patient data; eOR conversions may introduce approximation.
Future Directions: Head-to-head GLP-1RA comparisons, longer-term safety (e.g., bone, pancreas, gallbladder), and evaluation in multimorbidity and diverse ancestries.
AIM: Glucagon-like peptide 1 receptor agonists (GLP-1RAs) have been established as effective treatments for type 2 diabetes, offering benefits beyond glycaemic control; however, their associations across multiple health outcomes remain insufficiently assessed. Thus, we conducted an umbrella review of meta-analyses of randomised controlled trials (RCTs) to comprehensively evaluate the broad spectrum of their effects. MATERIALS AND METHODS: We conducted a systematic search of PubMed/MEDLINE, Embase, CINAHL, and Google Scholar through June 13, 2025, to identify meta-analyses of RCTs assessing the effects of GLP-1RAs on var
2. Pyruvate kinase M2 -mediated histone lactylation alters three-dimensional genomic architecture in polycystic ovary syndrome.
Nuclear PKM2 drives histone H3 lactylation (K9/K18) and 3D chromatin reorganization that upregulates steroidogenic genes (CYP17A1, CYP11A1), producing PCOS-like phenotypes in mice. Whole-organ imaging confirmed increased small follicles, and pharmacologic blockade of nuclear PKM2 reversed phenotypes and transcriptomes to near-wild-type states.
Impact: Provides a unifying, targetable epigenetic mechanism linking ovarian metabolic stress to gene dysregulation and PCOS phenotypes, with in vivo reversibility.
Clinical Implications: Identifies nuclear PKM2 as a potential therapeutic target; motivates development of PKM2 nuclear translocation inhibitors and exploration of histone lactylation readouts in PCOS.
Key Findings
- Nuclear PKM2 associates with enhanced histone H3 lactylation at K9 and K18 and reshapes 3D genome (compartment switching, TAD fusion, new enhancer–promoter loops).
- Upregulation of steroidogenic genes (CYP17A1, CYP11A1) accompanies chromatin changes.
- Granulosa cell Pkm2 overexpression induces PCOS-like traits (disrupted estrous cycles, hyperandrogenism, increased small follicles).
- Pharmacologic inhibition of nuclear PKM2 reverses PCOS-like phenotypes and restores transcriptomes.
Methodological Strengths
- Multi-omics integration (chromatin, transcriptome) with 3D genome analyses and functional validation.
- In vivo gain- and loss-of-function with pharmacologic rescue demonstrating reversibility.
Limitations
- Preclinical models may not fully recapitulate human PCOS heterogeneity.
- Target safety and specificity of nuclear PKM2 inhibition in human ovaries remain to be established.
Future Directions: Validate PKM2–lactylation signatures in human PCOS tissues; develop selective inhibitors of PKM2 nuclear translocation; test therapeutic modulation in clinical studies.
Polycystic ovary syndrome (PCOS) is a frequent endocrine and metabolic imbalance that typically occurs in women of reproductive age. Its molecular pathophysiology is yet unknown, especially the ovarian cellular metabolic inefficiency that causes the transcriptional dysregulation of key genes linked to PCOS. Here, we discovered that one transcriptional-like regulator that causes PCOS is nuclear pyruvate kinase M2 (nPKM2). Using multiomics techniques, we show that enhanced lactylation of histone 3 on lysine residues 9 and 18 is linked to nPKM2 binding to the genome, changing the three-dimensional architecture of the genome. Genomic compartment switching, topologically associated domain fusion, and novel enhancer-promoter interactions subsequently enhance the expression of PCOS-related genes, including CYP17A1 and CYP11A1. In mice, ectopic expression of Pkm2 in female GCs consistently presented PCOS-like traits, such as interrupted estrous cycles, hyperandrogenism, and so on. Importantly, whole-organ tracing imaging directly unfolded the number of small follicles, which increased highly in Pkm2-tdtomato transgene mice compared with control. Furthermore, pharmacological inhibition of the nuclear accumulation of PKM2 mitigated PCOS-like symptoms in mice and restored a wild-type-like transcriptome. This study demonstrates the important function of PKM2-mediated histone lactylation in regulating the three-dimensional chromatin architecture and highlights PKM2 as a potential therapeutic target for PCOS treatment.
3. Polygenic risk score and cluster-based analysis suggests links between type 2 diabetes and vascular dementia in the KARE study.
In 33,136 older adults, higher T2D polygenic risk was linked to vascular dementia but not Alzheimer’s disease. Cluster-partitioned PRS pinpointed the hyperinsulinemia pathway as a key driver of vascular dementia risk, suggesting insulin-related metabolic abnormalities as targets for early risk stratification and prevention.
Impact: Links a specific metabolic-genetic pathway (hyperinsulinemia) to vascular dementia risk, refining the T2D–dementia relationship and enabling pathway-informed precision prevention.
Clinical Implications: Supports early dementia risk stratification in T2D using pathway-informed PRS and prioritizing aggressive insulin-resistance management to reduce vascular dementia risk.
Key Findings
- Higher overall T2D polygenic risk score associated with increased vascular dementia risk, not Alzheimer’s disease.
- Partitioned PRS revealed hyperinsulinemia-specific genetic risk strongly linked to vascular dementia incidence.
- Findings suggest insulin-related metabolic abnormalities as mechanistic contributors to vascular dementia.
Methodological Strengths
- Large cohort (n=33,136) with dementia subtype resolution and cluster-based partitioned PRS.
- Focus on pathway-specific genetic architecture enables mechanistic inference beyond aggregate PRS.
Limitations
- Observational genetic association; residual confounding and population specificity (older Chinese cohort) may limit generalizability.
- Clinical utility of pathway-informed PRS requires prospective validation and integration with clinical factors.
Future Directions: Prospective validation across ancestries; integrate pathway-PRS with biomarkers of insulin resistance and vascular injury to guide preventive interventions.
Type 2 diabetes is an established risk factor for dementia. However, how its genetic heterogeneity affects different dementia subtypes remains unclear. In this study, we investigate the associations between genetic risk of type 2 diabetes and dementia subtypes among 33,136 older Chinese adults from the KARE cohort. We find that a higher overall polygenic risk score for type 2 diabetes is significantly associated with an increased risk of vascular dementia, but not Alzheimer's disease. Further analyses using cluster-specific partitioned polygenic score show that elevated genetic risk specific to the hyperinsulinemia pathway is strongly associated with increased incidence of vascular dementia. These findings highlight the potential role of insulin-related metabolic abnormalities in the pathogenesis of vascular dementia and provide genetic evidence to support the use of the hyperinsulinaemia pathway as a clinically relevant marker for early risk stratification and precision prevention strategies.